| 201 |
23238683 | All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib. | 2012 Dec |
1 |
| 202 |
25031941 | Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia. | 2012 May |
1 |
| 203 |
20473616 | Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. | 2011 Jan |
1 |
| 204 |
20807497 | A magnetic bead-based protein kinase assay with dual detection techniques. | 2011 Jan 1 |
1 |
| 205 |
20942869 | An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib. | 2011 Apr |
2 |
| 206 |
20945321 | Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. | 2011 Mar 1 |
1 |
| 207 |
20952511 | p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. | 2011 Jan |
1 |
| 208 |
20962097 | Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. | 2011 Jan |
1 |
| 209 |
21098337 | Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. | 2011 Jan 15 |
1 |
| 210 |
21148814 | Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. | 2011 Feb 10 |
1 |
| 211 |
21220945 | Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. | 2011 Jan 15 |
2 |
| 212 |
21226671 | Dasatinib: an anti-tumour agent via Src inhibition. | 2011 Apr |
2 |
| 213 |
21263099 | Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. | 2011 Mar 1 |
1 |
| 214 |
21264552 | A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. | 2011 Feb |
3 |
| 215 |
21385851 | Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. | 2011 May 12 |
1 |
| 216 |
21454413 | Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. | 2011 May 15 |
1 |
| 217 |
21463117 | The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. | 2011 May |
2 |
| 218 |
21505103 | The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. | 2011 May 1 |
1 |
| 219 |
21528941 | Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. | 2011 Jun 1 |
1 |
| 220 |
21575924 | Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. | 2011 Apr |
1 |
| 221 |
21632458 | Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀? | 2011 |
1 |
| 222 |
21633166 | Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. | 2011 Jul |
1 |
| 223 |
21654685 | HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib. | 2011 Jun 28 |
1 |
| 224 |
21660654 | Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2011 Sep |
1 |
| 225 |
21670084 | Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. | 2011 Sep 1 |
1 |
| 226 |
21718141 | Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. | 2011 Nov |
1 |
| 227 |
21792346 | Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. | 2011 |
2 |
| 228 |
21863287 | RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. | 2011 Sep |
1 |
| 229 |
21902298 | Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. | 2011 Sep 10 |
3 |
| 230 |
21908430 | The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. | 2011 Nov 10 |
1 |
| 231 |
21931113 | Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2011 Dec 15 |
1 |
| 232 |
21990409 | Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. | 2011 Nov 10 |
1 |
| 233 |
22035738 | Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. | 2011 Jun |
1 |
| 234 |
22087818 | Effects of BCR-ABL inhibitors on anti-tumor immunity. | 2011 |
2 |
| 235 |
19768693 | Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. | 2010 Jun |
1 |
| 236 |
19798095 | Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. | 2010 Jan |
1 |
| 237 |
19924787 | Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. | 2010 Jan 15 |
1 |
| 238 |
20001232 | Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2010 Feb |
1 |
| 239 |
20038231 | Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. | 2010 Mar |
1 |
| 240 |
20047099 | Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation. | 2010 Jan |
2 |
| 241 |
20072833 | Dasatinib. | 2010 |
3 |
| 242 |
20072840 | Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. | 2010 |
1 |
| 243 |
20108303 | Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. | 2010 Mar 15 |
2 |
| 244 |
20111071 | Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. | 2010 Apr |
5 |
| 245 |
20113198 | Dasatinib in solid tumors. | 2010 Mar |
1 |
| 246 |
20139391 | Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. | 2010 Feb |
2 |
| 247 |
20139893 | Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. | 2010 Jul |
1 |
| 248 |
20143399 | The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. | 2010 Nov 1 |
3 |
| 249 |
20145167 | Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. | 2010 Feb 15 |
2 |
| 250 |
20197479 | New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. | 2010 Mar 15 |
1 |